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PURPOSE. Retinal photocoagulation and nondamaging laser therapy are used for treatment of
macular disorders, without understanding of the response mechanism and with no rationale
for dosimetry. To establish a proper titration algorithm, we measured the range of tissue
response and damage threshold. We then evaluated safety and efficacy of nondamaging retinal
therapy (NRT) based on this algorithm for chronic central serous chorioretinopathy (CSCR)
and macular telangiectasia (MacTel).
METHODS. Retinal response to laser treatment below damage threshold was assessed in
pigmented rabbits by expression of the heat shock protein HSP70 and glial fibrillary acidic
protein (GFAP). Energy was adjusted relative to visible titration using the Endpoint
Management (EpM) algorithm. In clinical studies, 21 eyes with CSCR and 10 eyes with
MacTel were treated at 30% EpM energy with high spot density (0.25-diameter spacing).
Visual acuity, retinal and choroidal thickness, and subretinal fluid were monitored for 1 year.
RESULTS. At 25% EpM energy and higher, HSP70 was expressed acutely in RPE, and GFAP
upregulation in Müller cells was observed at 1 month. Damage appeared starting at 40%
setting. Subretinal fluid resolved completely in 81% and partially in 19% of the CSCR patients,
and visual acuity improved by 12 6 3 letters. Lacunae in the majority of MacTel patients
decreased while preserving the retinal thickness, and vision improved by 10 letters.
CONCLUSIONS. Heat shock protein expression in response to hyperthermia helps define the
therapeutic window for NRT. Lack of tissue damage enables high-density treatment to boost
clinical efficacy, therapy in the fovea, and retreatments to manage chronic diseases.
Keywords: hyperthermia, retina, laser therapy, nondamaging, heat shock protein, macular
disorders, macular telangiectasia, central serous chorioretinopathy
Disorders of the macula, the central area of the retinacontaining structures responsible for high-resolution
vision, can lead to vision impairment and blindness, if
untreated. Macular disorders include age-related macular
degeneration (AMD), the leading cause of untreatable blindness
in the world, diabetic macular edema (DME), chronic central
serous chorioretinopathy (CSCR), and idiopathic macular
telangiectasia (MacTel). While these disorders have different
underlying pathophysiology, treatment for each disease is
complicated by proximity to the central part of the macula,
the fovea, which is vital for high-acuity vision. Laser photoco-
agulation, either alone or in combination with anti-VEGF
pharmacotherapy or steroids, is the standard of care for retinal
diseases including proliferative diabetic retinopathy,1 DME,2
CSCR,3 and retinal vein occlusions.4 However, conventional
photocoagulation produces retinal damage, which is unaccept-
able near the fovea and precludes multiple retreatments,
essential for chronic diseases.
Fundamentally, photothermal therapy is based on conver-
sion of absorbed laser light in the retinal pigment epithelium
(RPE) and choroid into heat. In photocoagulation, diffusion of
heat from the RPE into the retina leads to thermal damage to
photoreceptors or, at higher settings, even to the inner retinal
cells. While destruction of a significant fraction of photorecep-
tors, the most metabolically active and numerous cells in the
retina, is desirable to reduce metabolic load and thereby
decrease secretion of angiogenic factors from ischemic retina in
order to limit neovascularization in proliferative diabetic
retinopathy, the role of sparse grid photocoagulation in
treatment of macular disorders has never been understood.
Several laser techniques have been developed to reduce
retinal damage compared to conventional photocoagulation
while maintaining therapeutic benefit. One technique, selective
RPE therapy (SRT), uses short laser pulses (~1 ls) to confine
heating during the pulse to melanosomes within RPE cells.5,6 A
similar technique with 3-ns pulses is called 2RT.7 With heat
confinement and sufficient laser energy, explosive vaporization
of melanosomes produces microbubbles that destroy RPE cells8
without thermal damage to the adjacent retina. Removal of the
cell debris, followed by proliferation and migration of the RPE
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from adjacent areas,9 is thought to clear the Bruch’s membrane
and rejuvenate RPE cells to provide the therapeutic effect.10
Another paradigm assumes that thermal stress to the RPE or
retinal cells, rather than tissue damage, is responsible for the
therapeutic effect of laser treatment in the macula. Trans-
pupillary thermotherapy (TTT) has been suggested as an
alternative to photocoagulation in cases of subfoveal leaks.11 In
this approach, 810-nm laser was applied with relatively low
average power and very long exposures (60 seconds) over a
wide spot on the retina (800 lm),12 producing a large heating
zone. However, lack of temperature control or titration in this
procedure resulted in frequent occurrences of significant
retinal damage.13 A pulsed version of a similar near-infrared
laser with smaller spot size (125 lm) replaced TTT for
nondamaging hyperthermia. The so-called subthreshold diode
micropulse (SDM) laser14 or a similar laser at 577-nm
wavelength15 delivers 100- to 300-ms bursts of pulses of 0.1
to 0.3 ms in duration, with the average power set below the
clinically detectable tissue damage threshold by adjustment of
the pulse duty cycle and peak power. Unlike SRT, the
individual micropulses have much (approximately 100 times)
lower peak power and much (100 times) longer duration, so
that thermal energy is not confined to melanosomes but rather
spreads over the whole RPE cell, resulting in cumulative
heating by a few degrees14 rather than microbubble formation.
Subthreshold diode micropulse has been shown to be effective
in the treatment of CSCR, reducing the subretinal fluid and
improving visual acuity, compared to untreated controls.16
However, lack of a well-defined dosimetry and titration
procedure is reflected in the variable results with this
technology.17–19 Moreover, it is not clear whether ‘‘micro-
pulse’’ modulation of the laser power provides any benefits
compared to continuous wave (CW) laser of the same average
power and duration.14 The key issue with either modality is to
properly titrate the laser settings below the damage threshold,
but within the range of clinical response in every patient.
We hypothesized that hyperthermia leads to protein
denaturation at a rate quantifiable as a temperature-dependent
chemical reaction, and that corresponding cellular responses,
such as heat shock expression or irreversible damage, are
triggered by the reduction in concentration of the critical
molecular components. The temperature-dependent reaction
rate is described by the Arrhenius equation, which is
parameterized by an activation energy and assumes the
absence of cellular repair during hyperthermia.20 The total
effect of this process during the laser pulse is described by the
integral of the denaturation rate over the duration of
hyperthermia. To assess the temperature distribution in tissue
during the laser pulse and the corresponding tissue effect, we
developed a retinal thermal model.20
Different levels of Arrhenius integral were found to
correspond to different clinical grades of retinal lesions, with
approximately an order of magnitude difference between the
distinguishable grades. To relate the highly nonlinear process
of retinal photocoagulation to the laser power and duration,
we developed an algorithm called Endpoint Management
(EpM), which adjusts the laser power and duration such that
a 103 increase in Arrhenius integral value corresponds to a
20% increase in the pulse energy (Fig. 1).21 Arrhenius integral
of X ¼ 1000 corresponds to a barely visible lesion, detectable
right after the exposure (within 3 seconds). We use such a
binary definition of the lesion visibility (yes or no) to simplify
titration in each subject. Ten times lower X corresponds to
lesions that become visible much later due to edema that
develops over approximately 30 seconds post laser exposure.
Arrhenius integral of X ¼ 1 corresponds to the damage
threshold of RPE. The EpM algorithm maps a clinically relevant
range of calculated Arrhenius integral values to linear steps in
pulse energy, normalized to a titration dose for producing a
barely visible burn at a particular duration (Fig. 1).21
Initial experiments with heat shock protein (HSP) expres-
sion following retinal exposures in mice indicated that HSP70
is upregulated for X > 0.1.22 Since the damage threshold is X¼
1, nondamaging thermal therapy corresponds to Arrhenius
values in the range of 0.1 < X < 1.22 Computational analysis of
the clinical laser settings confirmed these estimates.14
Within the range of nondamaging hyperthermia, RPE cells
respond to thermal stress by expression of HSP.22 Heat shock
proteins are known to act as chaperones for protein refolding,
to inhibit apoptosis, and to downregulate inflammation.23
Induction of these proteins by thermal stress, and activation of
the associated downstream repair pathways, is thought to
rejuvenate RPE cells and restore their function.24
In the retina itself, it has been reported that activation of
Müller cells in and around laser lesions (observed by glial
fibrillary acidic protein [GFAP] expression) may be responsible
for wound contraction and restoration of the photoreceptor
layer after thermal damage.25 Although the exact mechanism of
photoreceptor migration into the lesion is not completely
understood, it was hypothesized to be mediated by Müller
cells, which initially fill the lesion and later contract, thereby
pulling in adjacent photoreceptors. This effect could be
especially interesting for treating MacTel since it is associated
with the focal loss of photoreceptors and is mediated by
dysfunction of Müller cells.26
Previous studies of the EpM algorithm in rabbits established
that, with titration for a barely visible lesion defined as 100%
energy on EpM scale, the 30% energy setting corresponds to
the RPE damage threshold.21 In this study, we first define the
cellular response window below the damage threshold and the
area of RPE activation by imaging the expression of HSP70 in
the RPE at various energies and applying live–dead fluorescent
assay to map the extent of tissue damage at these settings.
Within this window, we also observe the long-term retinal
response to nondamaging laser therapy. These preclinical
studies helped define the desirable energy range and laser spot
density in the treatment pattern. We then applied the EpM
protocol with these settings to test the clinical efficacy of
nondamaging retinal laser therapy (NRT) in treatment of
chronic CSCR and MacTel. In this article, we describe the 1-
year results of these studies.
FIGURE 1. Endpoint Management algorithm. Dashed lines, corre-
sponding to different clinical grades, differ by an order of magnitude in
Arrhenius integral X. The red area corresponds to the damaging
settings and green to the nondamaging range of HSP expression; blue is
below the threshold for cell response. Titration of 100% corresponds to
barely visible lesion (BV) observed at 3 seconds.
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METHODS
Laser Treatments in Rabbits
A total of 15 Dutch-belted rabbits were used in accordance with
the ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research, with approval from the Stanford University
Animal Institutional Review Board. The rabbits were anesthe-
tized with ketamine hydrochloride (35 mg/kg) and xylazine (5
mg/kg). Pupil dilation was achieved by one drop each of 1%
tropicamide and 2.5% phenylephrine hydrochloride. Topical
tetracaine hydrochloride (0.5%) was used for local anesthesia. A
Mainster wide-field retinal contact lens (OMRA-WF; Ocular
Instruments, Bellevue, WA, USA) was used with hydroxypropyl
methylcellulose as a contact gel. The conversion of aerial to
retinal beam size with the contact lens on the rabbit eye was
calculated to be 70% by comparing pattern spacing on viability-
stained samples to aerial pattern spacing.
A 577-nm PASCAL Streamline laser (Topcon Medical Laser
Systems, Santa Clara, CA, USA) was used to deliver uniform
spots with 200-lm aerial diameter (140-lm on retina).
Endpoint Management titration was performed with 20-ms
pulses and visibility was evaluated 3 seconds after laser
delivery. Treatment grids of 3 3 3 or 5 3 5 laser spots were
applied with energies of 20%, 25%, 30%, 40%, and 100%
according to the EpM algorithm. An additional 114% energy
point was added by increasing laser power without changing
the 20-ms pulse duration. Intense marker burns were applied
to outline the treatment areas and help locate nondamaging
treatment patterns in subsequent analysis. Treatment was
applied 7 hours before euthanasia for detection of acute HSP
expression and viability staining. For tissue pathology and
scanning electron microscopy, animals were euthanized 1 day
and 1 hour after laser treatment, respectively, for best
detection of structural changes. Immunohistochemistry to
detect long-term expression of GFAP was done at 4 weeks.
Damage Threshold Determination
For viability staining, the eye was enucleated immediately after
euthanasia, the anterior segment of the globe was removed,
and the retina was manually peeled off of the RPE. The RPE–
choroid–sclera sample was rinsed briefly in balanced salt
solution (BSS) and then immersed in 2 lM calcein AM/12 lM
EthD-III (Viability/Cytotoxicity Assay; Biotium, Hayward, CA,
USA) solution for 30 minutes in a covered petri dish. Tissue
samples were promptly imaged with fluorescence microscopy.
For histologic analysis, eyes were fixed in 1.25% glutaralde-
hyde/1% paraformaldehyde in cacodylate buffer (pH 7.2)
overnight at room temperature. The tissue was then postfixed
in osmium tetroxide, dehydrated with a graded series of
ethanol, and processed with propylene oxide. Tissue was
embedded into epoxy resin (Embed 812; Electron Microscopy
Sciences, Port Washington, PA, USA). One-micrometer sections
for light microscopy were cut on an ultramicrotome (Reichert-
Jung Ultracut E; Leica, Deerfield, IL, USA), stained with
toluidine blue, and photographed on a light microscope
(Eclipse E1000; Nikon, Tokyo, Japan).
For scanning electron microscopy (SEM) analysis, the sclera,
choroid, and RPE were fixed in 1.25% glutaraldehyde/1%
paraformaldehyde in 0.2 M sodium cacodylate buffer at room
temperature for 30 minutes. The tissue was then fixed for an
additional 18 hours at 48C, rinsed in cacodylate buffer, and
postfixed in 1% osmium tetraoxide in 0.2 M cacodylate buffer
(pH 7.4). The tissue was washed with distilled water,
dehydrated in a series of ethanols, critical point dried, mounted
on stubs, and plasma coated with Au/Pd (Denton Vacuum,
Moorestown, NJ, USA). Samples were imaged with a Hitachi S-
3400N VP-SEM (Hitachi, Pleasanton, CA, USA).
Immunohistochemistry
For whole-mount immunostaining of the RPE for HSP70
expression, the sclera, choroid, and RPE were fixed in
HistoChoice MB tissue fixative (Amresco LLC, Solon, OH, USA)
for 4 hours at room temperature. The tissue was then washed in
phosphate-buffered saline (PBS) and blocked for 1 hour at room
temperature in PBS containing 5% normal goat serum. The
tissue was incubated in 0.027 mg/mL mouse mAb anti-HSP70/72
(C92F3A-5, no. ADI-SPA-810-F; ENZO Life Sciences, Farmingdale,
NY, USA) in PBS containing 1% normal goat serum at 48C
overnight. This was followed by three 15-minute washes in PBS
and incubation in PBS containing 0.027 mg/mL CF594 goat anti-
mouse IgG (HþL) secondary antibody (cat. no. 20111; Biotium)
for 1 hour at room temperature. The tissue was then washed
three times for 15 minutes in PBS. The RPE and choroid were
carefully separated from the sclera, mounted with glycerol
mounting medium (ab188804; Abcam plc, Cambridge, UK), and
imaged with a confocal microscope (Leica SP8 WLL; Leica
Microsystems, Inc., Buffalo Grove, IL, USA).
To study long-term expression of GFAP, eyes were
enucleated 4 weeks after laser treatment and fixed in 4%
paraformaldehyde with 5% sucrose. Samples were processed
and embedded in paraffin, and slides were prepared with 5-lm
sections. Tissue sections were deparaffinized and high-temper-
ature antigen retrieval (85–908C) was performed in EDTA (pH
9) buffer for 1 hour. Bovine serum albumin (BSA, 10%) was
used as blocking solution for 1 hour at room temperature.
Sections were labeled with primary antibody raised against
GFAP (SC-6170, goat polyclonal), which is activated in Müller
cells in response to retinal injury. The antibody was diluted to
1:25 with PBS/Triton with 1% BSA, and slides were incubated
overnight at 48C. Slides were rinsed in PBS/Triton, incubated
with 1:200 FITC (SC-2024) at room temperature for 1 hour,
washed again with PBS/Triton, and stained with a fluorescent
DNA stain (DAPI). Vectashield mounting medium (H-1000;
Vector Laboratories, Inc., Burlingame, CA, USA) was used and
sections were imaged with a fluorescent microscope (Nikon
Eclipse TE300).
Computational Modeling
A finite-element model of 532-nm laser heating of the rabbit
retina published by Sramek et al.20 was adapted for 577 nm and
used to predict temperature rise and tissue response using the
Arrhenius damage integral. The adapted model, implemented
with a computational package (COMSOL Multiphysics 5.0;
Natick, MA, USA), reduces the absorption coefficients in the
pigmented layers by 25% to account for lower melanin
absorption at 577 nm while increasing absorption coefficients
in vascular layers by 25% to account for higher hemoglobin
absorption.27 Using the most common experimental titration
value in rabbits, the power producing barely visible burns
(100% EpM energy setting) was calculated with 70 mW for 20-
ms pulse and 140-lm beam, corresponding to the beam size on
the rabbit retina. The EpM algorithm was used to calculate
lower energy settings (20%, 25%, 30%, 40%) while higher
energy setting (114%) was calculated by increasing the power.
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Previous correlation of Arrhenius damage integrals and HSP
expression14,22 suggested that Arrhenius values of X¼ 0.1 and
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X¼ 1 are the key reference points, where HSP expression and
cell damage, respectively, are predicted to begin. One
unmeasured parameter, the total transmission of the laser
through the eye to the retina, was adjusted to 62% to match the
diameter of HSP expression (X¼ 0.1) at 30% energy setting.
Patient Selection
This was a prospective, nonrandomized, interventional case
series approved by the Ethics Committee of the Hospital de
Cĺınicas de Porto Alegre, Federal University of Rio Grande do Sul,
and adhered to the tenets of the Declaration of Helsinki. Patients
were older than 18 years of age, with CSCR and symptoms
presented for more than 4 months or macular telangiectasia type
2 (MacTel). The CSCR was confirmed by the presence of one or
more leakage points in the fluorescein and/or indocyanine green
angiography, subretinal fluid in the optical coherence tomogra-
phy (OCT) (Spectralis; Heidelberg Engineering, Heidelberg,
Germany) and increased choroidal thickness in the enhanced
depth imaging (EDI) OCT mode. Macular telangiectasia was
diagnosed by bilateral typical appearance of telangiectasic vessels
temporal to the fovea on fluorescein angiography with late
leakage and OCT. Best-corrected visual acuity (BCVA) measured
by the Early Treatment Diabetic Retinopathy Study (ETDRS)
protocol was in the range from 20/20 to 20/400. Patients
included in the study did not have any other retinal or choroidal
disease that could present with similar characteristics. They also
had not had prior macular laser treatment, or intravitreal steroids
within the last 4 months, or anti-VEGF treatments during the last
month prior to the laser treatment. Patients were not eligible if
they had either retinal thickening due to the epiretinal membrane
or vitreomacular traction syndrome or had undergone major
ocular surgery (including cataract surgery) within 6 months.
Treatment Procedures and Evaluation of the
Therapeutic Effect
The baseline examination included ETDRS BCVA, slit-lamp
examination of the anterior segment, indirect ophthalmoscopy,
color fundus photography using CR-2 retinal camera (Canon
U.S.A., Melville, NY, USA), fluorescein angiography (FA), and
fundus autofluorescence (FAF) using HRA-2 (Heidelberg Retina
Angiograph; Heidelberg Engineering). Baseline macula and
choroidal thickness and presence of the subretinal fluid were
evaluated by OCT (Spectralis). Subfoveal choroidal thickness
was defined as the distance from the outer edge of the
hyperreflective RPE in the center of the fovea to the inner
sclera, using the Spectralis built-in linear measuring tool.
Patients eligible for the therapy received the laser treatment
as described below; ETDRS BCVA and central macular
thickness (CMT) measurements by OCT were performed
monthly for 12 months of follow-up. Fluorescein angiography
was repeated after 3, 6, and 12 months. Laser treatment could
be repeated up to every 3 months if subretinal fluid persisted
or recurred. The effect of the laser treatment was measured by
the improvement in visual acuity, assessment of serial retinal
autofluorescence, resolution of the retinal detachment and/or
subretinal fluid by OCT, and evaluation of leakage areas on FA.
Potential adverse events have been monitored with visual
acuity, clinical examination, FA, and OCT. In MacTel patients,
retreatment could be performed every 6 months if disease was
progressing or persistent lacunae remained.
Clinical Laser Settings and Endpoint Management
Algorithm
PASCAL laser (Topcon Medical Laser Systems) with 577-nm
wavelength and 200-lm retinal spot size was applied via the
Area Centralis HD contact lens (Volk Optical, Mentor, OH, USA).
Treatment was based on OCT macular thickness map and on
the increased autofluorescence area, which included areas of
thickened and nonthickened retina. Retinal treatment begins
with titration of the laser power to a minimally visible retinal
lesion endpoint outside vascular arcades. As ophthalmoscopic
visibility of the lesion changes over time, its appearance must be
evaluated at a consistent time point after the laser application.
For practical clinical usability, evaluation time point of 3
seconds was defined for this protocol. During titration, pulses
of 15-ms duration have been used. The titration pulse energy
corresponding to a minimally visible burn was assigned the
100% on EpM settings, and the treatment pulse energy was then
defined as a percentage of this titration energy. Each energy
level corresponds to a unique pair of laser power and pulse
duration as described previously.21
Treatment was performed at 30% energy, the level
established as the highest nondamaging setting in animal
studies.21 Graphic user interface of the EpM allows keeping
some of the corner spots of the pattern at 100% energy to
produce visible landmarks for orientation. Treatment was
initially applied using the round macular grid pattern (rin¼500
lm, rout ¼ 3000 lm) with landmarks on, using 0.25-diameter
spacing between the laser spots. To expand the treated area,
additional 2 3 2 patterns were applied without landmarks
inside the inner radius of the macular grid, and 3 3 3 patterns
without landmarks were applied outside the grid. Laser
patterns covered both the thickened and nonthickened retina
in the posterior pole as determined by the OCT and by
increased autofluorescence. During retreatments, all the
landmarks were turned off.
Statistical Analysis of Clinical Data
For statistical analysis, the visual acuity data were converted to
logarithm of the minimum angle of resolution (logMAR). All
clinical data were reported as mean 6 standard error of mean
(SEM). The Wilcoxon signed rank test was performed to assess
significance of the change in visual acuity and retinal thickness
compared to the baseline. Average values of the retinal
thickness and visual acuity are plotted with the error bar
representing the standard error of the mean.
RESULTS
Preclinical Studies of Nondamaging Hyperthermia
Damage to the RPE cells after laser exposure in rabbit eyes was
checked using three methods: viability/cytotoxicity staining
(Biotium), histology, and SEM. For viability/cytotoxicity stain-
ing, four eyes were treated with a total of 250 laser spots at
30% energy, 250 spots at 40%, and 54 spots at 100%. At 30%
energy, none of the laser spots showed any dead cells. An
example of the pattern area with no visible changes is shown
in Figure 2A. At 40% energy, damage was visible in 69% of the
laser spots. Figure 2B presents a part of the 5 3 5 pattern at
40% energy, with dead RPE cells seen with EthD-III fluorescent
red–stained nuclei. At 100% energy, all of the laser spots
resulted in RPE cell death. The 3 3 3 pattern in Figure 2C has
red nuclei, as well as RPE cells that are missing entirely. The
hazy red seen in several spots arises from out-of-focus staining
of dead photoreceptors fused onto the RPE.
Histology of the retina lasered 1 day before enucleation
shows unblemished tissue at 30% (Fig. 2D), slight damage in
the 50% area delineated by yellow arrows (Fig. 2E), and clearly
damaged 100% area (Fig. 2F) with outer segments fused to the
RPE and pyknotic nuclei in the outer nuclear layer. Scanning
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electron microscopy shows similar results, with undisturbed
RPE at 30% energy except for a single cell indicated by the
yellow arrow in Figure 2G, while 50% energy produced a larger
damage zone (Fig. 2H). At 100% energy the outer segments
were fused onto the RPE (Fig. 2I). Results from all three
methods of analysis indicate that the 40% energy setting or
greater is damaging while below 30% is nondamaging.
HSP70 Expression
Confocal microscope images of immunostained RPE with laser
patterns of 20%, 25%, 30%, 40%, 100%, and 114% energy were
analyzed for expression of HSP70. No expression was observed
at 20% energy from a total of 250 observed laser spots. For 25%
energy (n¼200), 57% of laser spots showed HSP70 expression
while 30% energy (n¼238) and 40% energy (n¼150) had 98%
and 99% expression, respectively. All laser spots at 100% (n ¼
54) and 114% (n¼ 54) had HSP expression. Figures 3a through
3c show patterns of laser spots at 25%, 30%, and 40% energy,
where each spot produces a disc of activated cells. In contrast,
at the 100% energy setting, expression occurs in a ring of cells
as can be seen in Figure 3D.
In each image, the expression areas were measured by
outlining the boundaries with elliptical lines, with the dotted
and solid lines indicating the outer and inner limits, where
applicable. The HSP expression areas were measured for all
immunostained laser spots, and damage zone diameters were
measured for viability/cytotoxicity-stained samples. The mean
values for each laser setting are plotted as an average area per
100 delivered laser spots in Figure 3E, along with predicted
expression areas from the computational model. Error bars
indicate the expression areas corresponding to the 25th and
75th percentiles. The distribution of outer expression diameters,
given as the geometric mean of the major and minor axes of the
ellipse, is plotted in histograms in Supplementary Figures S1A
and S1B for damage and HSP expression, respectively.
A computational model of laser heating of the retina was
used to estimate the temperature rise during treatment.
Supplementary Figure S2 shows thermal maps of peak
temperature rise for 30% (Supplementary Fig. S2A) and 100%
(Supplementary Fig. S2B) settings and the maximum RPE
temperature course for 25%, 30%, 40%, and 100% settings
(Supplementary Fig. S2C). Arrhenius integrals were calculated
from these temperature courses to predict the size of the
damage area (X > 1) and HSP70 expression area (0.1 < X < 1).
These are plotted for the experimentally measured settings in
Supplementary Figure S3, with the dotted lines outlining the
areas of HSP expression and solid lines outlining areas of
damage. The ring pattern of HSP expression at 100% settings
illustrates the fact that dead RPE cells do not express HSP,
thereby defining the upper bound of X < 1. Figure 3E plots the
total expression area and total damage area per 100 laser spots,
as predicted by the model. For example, with the 30% energy
setting and 200-lm spots, the predicted expression area is 0.71
mm2 per 100 spots.
Glial Fibrillary Acidic Protein Expression
Glial fibrillary acidic protein expression associated with
activation of glial cells after retinal photocoagulation is known
to peak around 1 month and disappear 4 months after the
treatment.25 To check whether Müller cells are also activated by
nondamaging thermal treatment, we applied immunohisto-
chemistry targeting GFAP at 1 month after laser treatment. As
shown in Figure 4, the 30% laser spot shows elevated expression
of GFAP in Müller cells in the center of the laser spot, with no
visible damage to the outer nuclear layer. The 100% laser lesion
shows highly increased expression of GFAP in Müller cells
across a larger part of the laser area, which extends down into
an area of photoreceptor damage. Activation extends to the
right of the treatment spot in both images due to proximity to
the next spot (not visible in these photos).
FIGURE 2. Determination of damage threshold. (A–C) Viability/cytotoxicity-stained RPE cells 7 hours after laser treatment at 30%, 40%, and 100%
energy setting in rabbits. (D–F) Histology of retina and RPE 1 day after laser treatment at 30%, 50%, and 100% energy. (G–I) Scanning electron
microscopy of RPE 1 day after laser treatment at 30%, 50%, and 100%.
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Based on these results, we defined the laser settings for
clinical testing at the upper bound of the nondamaging
regime—30% energy on the EpM scale. To maximize the tissue
response and associated clinical efficacy, we decided to apply
patterns with much higher spot density than in conventional
photocoagulation: Spots were separated by 0.25 diameters
rather than 2 diameters in the conventional macular grid. Unlike
conventional photocoagulation associated with retinal damage,
NRT enables high-density treatment due to lack of tissue
damage, which might result in much higher clinical efficacy
than conventional photocoagulation, among other benefits.
Clinical Results With CSCR
To study the clinical efficacy of NRT in treatment of chronic
CSCR, 21 eyes from 20 patients (15 male and 5 female) with
chronic CSCR were enrolled. To exclude patients with high
potential for spontaneous resolution of the subretinal fluid,
only patients with at least 4 months of symptoms were
enrolled, and the mean duration of CSCR prior to the treatment
was 11 6 4 months. The average age on enrollment was 56 6
17 years. Typical power range in titration with 200-lm spot
diameter and 15-ms pulses was 90 to 150 mW, with an average
of 126 6 14 mW. Treatment was performed using 30% of the
titration energy, with 0.25-diameter spot spacing in all the
PASCAL patterns: macular grid, 2 3 2 and 3 33 square patterns.
A graphical user interface for adjustment of the laser
parameters is shown in Figure 5A. The average number of
spots per treatment was 548 6 212. The treatment spots
applied at 30% energy settings could not be detected clinically,
nor by OCT, FAF, or FA at any time point during the 12-month
follow-up. Autofluorescence image of the fundus 1 month after
the treatment reveals the titration spots below the arcade
(pointed to by white arrows in Fig. 5B) and landmark burns
(100% energy) in the macular grid (pointed to by black arrows
in Fig. 5B). None of the other treatment locations are visible.
One example of a response to NRT in a CSCR patient is
shown in Figure 6. In this particular case, the 61-year-old
patient had had chronic CSCR for more than 6 months and
presented with serous retinal detachment and visual acuity of
20/60. Thickness of the choroid at baseline was 165 lm, as
indicated by yellow bar in Figure 6A. One month after the
treatment, the CMT decreased significantly and visual acuity
increased to 20/30. Choroidal thickness decreased to 145 lm
as shown in Figure 6B. After two treatments, subretinal fluid
completely resolved and visual acuity improved to 20/20.
Choroidal thickness reached 135 lm as shown in Figure 6C.
Two other clinical examples demonstrating effective resolution
of subretinal fluid are presented in Supplementary Figures S4
and S5.
On average, CMT decreased following laser treatment from
362 6 11 to 283 6 9 lm (P ¼ 0.001) (Fig. 7A). In 81% of
patients, the subretinal fluid was completely resolved, and in
19% there was only minimal fluid left. Choroidal thickness also
decreased after laser treatment. Average subfoveal choroidal
thickness at baseline was 349 6 20 lm. It decreased to 290 6
15 lm after 3 months and remained stable over 1-year follow-
up (Fig. 7B), with a final thickness of 293 6 17 lm at 12
months (P ¼ 0.005). Patients with complete resolution of
subretinal fluid on OCT had no leakage on FA. In patients with
partial resolution of the fluid, some residual hyperfluorescence
could still be observed. Patients gained, on average, 12.2 6 3.0
ETDRS letters in BCVA at 2 months, which remained steady by
12 months (12.5 6 4.0, P < 0.001) as shown in Figure 7C.
Subretinal fluid resolved in 16% of patients after one
treatment, while 58% required one retreatment after 3 months
due to either recurrent fluid or incomplete fluid resolution.
Sixteen percent of patients received a second retreatment, and
the remaining 10% received a third retreatment, that is, a total
of four laser treatments, as summarized in the Table. The
average number of treatments was 2.2 per eye. There were no
adverse events related to the treatment. No visible laser marks
at the 30% treatment settings could be detected either by
clinical observation, OCT, FAF, or FA during 12 months of
follow-up. There were also no visible marks of any cumulative
retinal damage after retreatments.
Clinical Results With MacTel
Ten eyes of five patients (one male and four females) with
MacTel type 2 (acquired and bilateral) and an average age of 56
6 17 years were enrolled in the study. Typical power in
titration with 200-lm spot diameter and 15-ms pulses was 120
mW, varying from 100 to 140 mW. Treatment was performed
using 30% of the titration energy and 0.25-diameter spot
spacing in all the PASCAL patterns: macular grid, 2 3 2 and 3 3
FIGURE 3. HSP70 expression in RPE. Expression area 7 hours after
laser treatment at (A) 25%, (B) 30%, (C) 40%, and (D) 100% energy.
Expression area is indicated by dotted lines. In 100%, solid line
indicates inner limit of HSP70 expression. (E) Average expression (red)
or damage (black) area per 100 spots for 25% (NHSP¼ 200), 30% (NHSP
¼ 238, Ndamage ¼ 250), 40% (NHSP ¼ 150, Ndamage ¼ 250), 100% (NHSP,
Ndamage ¼ 54), and 114% (NHSP ¼ 54) energy. Solid bars show model
predictions while striped bars depict experimental measurements.
Error bars on experimental measurements give interquartile (25%–
75%) range.
Nondamaging Retinal Laser Therapy IOVS j May 2016 j Vol. 57 j No. 6 j 2493
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935270/ on 05/09/2016
3 square patterns. The average number of spots per treatment
was 382. The treatment spots applied at 30% energy settings
could not be detected clinically or by OCT, FAF, or FA. After 1
month, some hyperreflective spots could be seen with infrared
imaging; however, FAF, OCT, and FA did not show any damage
to outer or inner retina.
Unlike the natural course of MacTel, which leads to
thinning of the central macula due to loss of photoreceptors,28
the average CMT in the treated eyes was stable during the 12-
month follow-up period: It went from 246 6 13 lm at baseline
to 241 6 14 lm (P ¼ 0.48) at 1 year. The inner and outer
retinal lacunae significantly decreased in 80% of the eyes, while
the central outer nuclear layer thickness remained the same as
at baseline, 68 6 6 vs. 69 6 8 lm, suggesting that the
decreased cavitation was not due to collapsed tissue as usually
happens with the natural progression of MacTel.
An example of intraretinal lacunae reduction by 50% in area
is shown in Supplementary Figure S6: It went from 0.08 mm2
at baseline (Supplementary Fig. S6A) to 0.04 mm2 at 12 months
(Supplementary Fig. S6B). In another patient, the outer nuclear
layer and the inner segment/outer segment (IS/OS) junction
line were completely missing at baseline (Figs. 8A–C). Five
months after treatment, and subsequently through the 12-
month follow-up period, the outer nuclear layer was partially
restored, with the external limiting membrane (Fig. 8D) and IS/
OS line (Fig. 8E) reappearing. The detailed retinal thickness
maps of this patient are shown in Supplementary Figure S7. In
two eyes of one patient with the most severe degeneration, the
FIGURE 4. GFAP expression in the retina. GFAP expression in the retina 4 weeks after laser treatment. Green fluorescent marker indicates GFAP
activation, while blue is DAPI staining of the nuclei. (A) Control area shows low background level of GFAP; (B) 30% laser lesion with GFAP
expression in the inner retina; (C) 100% laser lesion with wider GFAP expression throughout the retina. Expression extends to the right of the
lesion due to proximity to the next spot in the pattern (not visible in this photo).
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FIGURE 5. Nondamaging retinal laser therapy with Endpoint Management. (A) Graphic user interface of the EpM software on Streamline PASCAL.
Red dots indicate the landmarks (100% energy, optional). Yellow dots indicate the locations to be treated at 30% energy. (B) Fundus
autofluorescence 1 month after NRT with landmarks that appear as spots with increased FAF (black arrows). Titration points are also visible in FAF
outside the arcades (white arrows). The 30% treatment spots were not visible clinically by OCT or FAF.
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lacunae did not decrease significantly, but the retina remained
stable for 1 year. There were no signs of disease progression or
further loss of photoreceptors throughout the follow-up in any
of the treated eyes. Visual acuity improved, on average, from
20/40 at baseline to 20/25 at 1 year. Four out of 10 patients
were retreated once during the follow-up period due to
persistent lacunae.
DISCUSSION
Preclinical animal studies using the EpM algorithm were
performed to determine the safe therapeutic window and
tissue response to hyperthermia. Figure 1 shows the titration
point and predicted therapeutic window (shaded in green)
based on the computational model of the retinal heating. Areas
colored in red correspond to damaging settings, those in green
to the nondamaging therapeutic range, and blue indicates
subtherapeutic. According to this plot, the damage threshold X
¼1 crosses the EpM line (solid black) at 40%. Our experimental
results with viability/cytotoxicity staining confirmed that the
damage threshold begins at 40% energy. Across four eyes in
three animals, 40% energy settings were damaging in 69% of
the 250 total delivered spots. The damage area increased with
energy, as shown in Figure 3E, and error bars indicate that
tissue response can vary, likely due to pigmentation fluctuation
across the eye. Nonetheless, treatments at 30% energy were
uniformly nondamaging following 250 experimental spots in
four different eyes, suggesting that this setting (in the middle of
the green zone) is sufficiently below the damage threshold to
account for normal pigment variation.
Heat shock protein expression in rabbits was observed
above 25% settings (Fig. 3E), which indicates that 25% energy
is the lower limit to the therapeutic window of NRT—a little
higher than the 20% predicted by the model. The HSP
activation area increased with energy up to 40%, but not
beyond that, since at higher energies the area of expression
became donut-shaped, with a dark center due to tissue
damage. Only the cells at the ‘‘warm’’ edges of the hot
coagulating spot survived the hyperthermia and expressed HSP.
Therefore, increasing laser energy above the damage threshold
is not expected to improve the therapeutic response. Instead,
FIGURE 6. Retinal response to NRT in patient with chronic CSCR. (A) Chronic serous retinal detachment with RPE irregularities, visual acuity (VA)
of 20/60. (B) Decrease in central macular thickness (CMT) and increase of visual acuity to 20/30 1 month after treatment. (C) Complete resolution
of subretinal fluid, with VA of 20/20, which remains stable for 1 year. Yellow vertical bars indicate subfoveal choroidal thickness, which decreased
from 165 to 135 lm.
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it just adds a damage zone in the center of the laser lesion,
which increases with energy, as can be seen in Figure 3E.
Experimentally, the HSP expression area and the damage
zone at 40%, 100%, and 114% were larger than computed with
the model (Fig. 3E), likely due to the cell size aliasing effect,
where an entire RPE cell is activated or damaged even if only a
part of it falls in the HSP expression zone or damage zone.
Given that the modeled expression zones at 100% and 114%
are approximately 20 lm in width (Fig. S3) and RPE cells are of
a similar size, partial overlap of the cells with the activation
area or damage zone would increase the observed expression
area. Despite this discrepancy, the model is useful for
understanding the activated HSP expression area and validating
the EpM methodology.
Activation area at 30% is a little smaller than the maximum
response (at 40% and beyond), but lack of tissue damage allows
application of much denser patterns than one could afford
with conventional damaging photocoagulation. For example, a
pattern with edge-to-edge spot spacing of 0.25-diameter would
cover 50% of the scanned area, while a pattern with 0 spacing
would cover 79% of the area. This is significantly more
coverage than with a conventional macular grid using 2-
diameter spacing, which only exposes 9% of the scanned area.
Such dense coverage is likely to boost the therapeutic
response.
Based on these studies, the laser settings for the NRT were
set at 30% energy to operate in the middle of the safe
therapeutic window and avoid tissue damage due to occasional
variations of pigmentation. To maximize the therapeutic
response, the spot spacing was set at 0.25 spot diameter. In
principle, it could be decreased to 0, but only after validating
that there is no tissue damage in sufficiently long follow-up.
The current study validated the lack of tissue damage, and we
now feel comfortable decreasing the spot spacing to 0,
especially in retreatment. However, we do not recommend
starting with such a tight spacing since titration criteria
(visibility of the lesion) may vary between physicians.
It is also important to emphasize that since the overarching
goal was the development of an algorithm for nondamaging
laser therapy of the macula, we have chosen a conservative
approach and titrated the laser in the periphery (beyond the
arcades), where the retinal coagulation threshold is lower than
in the macula. Areas of enhanced scattering (edema) and
reduced pigmentation will also experience lower temperature
rise and the tissue response will be diminished accordingly.
However, we prefer occasional undertreatment rather than
local titration in the macula, which will produce tissue damage.
Results of this trial confirm that despite these conservative
settings, NRT was effective in treatment of chronic CSCR and
MacTel, without tissue damage.
Mechanisms of action leading to therapeutic benefits
remain to be explored in more detail. Protein misfolding and
aggregation in cells is a fundamental component of aging.29
Normally, HSPs refold the damaged proteins and thereby
protect cells from protein aggregation and associated proteo-
toxicity.30 However, transcriptional pathways, including heat
shock factor (HSF1) potency, decline in aging cells,31 leading to
a decrease in protein quality control, which in turn contributes
to protein aggregation commonly observed in neurodegener-
ative diseases.32 Induction of HSP in aging cells helps maintain
the protein homeostasis by refolding the damaged proteins,
thereby promoting longevity and rejuvenating cellular func-
tions. In addition, molecular chaperones such as HSP27 and
HSP70 have antiapoptotic functions and can prevent depletion
of essential cell populations in degenerative processes.33
Therefore, enhanced synthesis of HSP and co-chaperones in
RPE in response to laser-induced thermal stress might bring
back normal physiology of these cells in aging and disease,
including enhanced capability of fluid pumping from the retina
and decrease in choroidal permeability.
Our results demonstrate significant reduction, and in a
majority (81%) of chronic CSCR patients, a complete resolution
of subretinal fluid, with corresponding improvement in visual
acuity. These outcomes are very different from the natural
course of chronic CSCR, which does not spontaneously resolve
in the majority of cases and usually progresses to further
decrease in visual acuity and morphologic damage to
photoreceptors.16,34 Nondamaging retinal therapy produced
no observable retinal damage at any of the follow-up time
points except for the visible landmarks, which remained visible
in IR and AF imaging. Recurrence of the intraretinal fluid
occurred in several patients after a few months, which
indicates that the improvement provided by NRT may fade
over time. However, retreatment with the same parameters
was found to be safe and effective, and no cumulative retinal
damage was detected over the follow-up period. Retinal
response to retreatment was similar to that for the first
treatment, and in some cases even better than the initial result.
One reason for better response to retreatment could be simply
the fact that retreatment was applied to much less edematous
retina than the first treatment. Reduced light scattering in this
FIGURE 7. Twelve-month follow-up after NRT in CSCR patients (N¼21
eyes). (A) Central macula thickness. (B) Subfoveal choroidal thickness.
(C) Gain in visual acuity (BCVA in ETDRS letters). Error bars represent
the standard error of mean.
TABLE. Number of Treatments in Patients During the 12-Month
Follow-Up Period
Number of treatments 1 2 3 4
Fraction of patients, % 16 58 16 10
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case would increase the temperature rise and improve
therapeutic response.
Macular telangiectasia type 2 is considered a neurovascular
degenerative disease associated with progressive neuroretinal
tissue loss, with an average annual progression of IS/OS break
area of 0.140 mm2,35 leading to severe visual impairment. Its
vascular aspects include telangiectasic vessels, usually tempo-
ral to the fovea, and in some cases choroidal neovasculariza-
tion. Although no precise cause has been determined for this
disease, Müller cell depletion has been associated with the
classic pathophysiologic findings.26 Anti-VEGF agents, steroids,
photodynamic therapy, photocoagulation, and recently sus-
tained release of the ciliary neurotrophic factor (CNTF)36 have
been tried for MacTel, but none have been found to be
effective in treatment of this disease so far.
Unlike natural history or previous therapeutic attempts,37
our initial results with MacTel patients are very encouraging: We
observed a decrease of the intraretinal lacunae and improve-
ment in visual acuity, and we did not detect progression of IS/OS
break area or outer retinal degeneration or in choroidal
neovascularization during the follow-up period. There even
seemed to be some signs of partial restoration of the
photoreceptor layer. Activation of Müller cells that we observed
in preclinical studies might play a role in this response since
contraction of activated Müller cells after conventional photo-
coagulation was hypothesized to be a driving force behind
migration of the photoreceptors into the lesion.25
Limitations of these studies include the small number of eyes
(21 in CSCR, 10 in MacTel) and absence of a control group;
therefore larger controlled clinical trials are being planned. It is
important to note, however, that CSCR patients had persistent
FIGURE 8. Retinal response to NRT in MacTel patient. (A) Baseline fundus color image. (B) Baseline fluorescein angiography with typical telangiectasic
vessels temporal to fovea. (C) Baseline OCT image with subfoveal cavitation and loss of IS/OS junction line integrity. (D) Partial restoration of outer
nuclear layer and external limiting membrane (arrow) at 5 months; (E) at 12 months, the IS/OS junction line became more visible (arrow).
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conditions for at least 4 months prior to laser treatment (11
months on average), increased choroidal thickness, and signs of
chronic RPE damage visible in autofluorescence and OCT.
Previous studies demonstrated that chronic CSCR has a very
limited resolution rate, with 92% of persistent leakage in the
observation-only control group, and therefore treatment is
warranted after confirming chronicity of the disease.16,38
The EpM algorithm is designed to normalize for pigmentation
variations and ocular transparency between individuals by
visible titration in each patient prior to treatment. Nevertheless,
there is still variation across the retina that is difficult to account
for. While we currently recommend 30% as a conservative
setting to ensure lack of damage based on clinical observations
and preclinical studies, increased therapeutic effect may be
possible with slightly higher settings. Recent measurement of
the damage threshold in the human eye39 showed that up to
35% EpM was nondamaging (Peter Karth, oral communication,
2016). Future developments in real-time tissue temperature
monitoring, including optoacoustic40,41 and laser speckle42
measurements, may allow for precise temperature control of
each individual laser pulse. This would allow us to adjust laser
settings in every spot and thereby fully compensate for variation
in retinal pigmentation and transparency in order to maximize
the safety and efficacy of NRT.
In summary, 1-year results with chronic CSCR and MacTel
demonstrated that NRT is efficient and safe for treatment of the
macula. Success in treatment of two disparate disorders by
activation of endogenous repair pathways, indicated by
upregulation of HSP in RPE and GFAP expression in Müller
cells, suggests that NRT might also be beneficial for treatment of
other outer retinal diseases with different pathophysiology,
including macular edema and diseases associated with RPE
deficiency such as drusen in dry AMD. Lack of tissue damage
allows for application of high-density treatment patterns to
increase therapeutic response and periodic retreatments for
chronic diseases. Availability of the EpM software on the market
enables immediate testing of NRT for various macular disorders.
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